Isabella Zhao

Isabella Zhao is an accomplished finance professional with extensive experience in investor relations and healthcare equity research. Currently serving as the Director of Investor Relations at CANbridge Pharmaceuticals Inc., Isabella successfully raised HK$604 million in an IPO on the Hong Kong Stock Exchange. Previous roles include Senior Healthcare Analyst at Caisse de dépôt et placement du Québec, where investment recommendations led to significant returns, and Senior Research Analyst at JPMorgan Chase & Co., overseeing healthcare coverage in Asia Pacific and completing a notable US$2 billion IPO for Samsung Biologics. Isabella's early career includes key positions at Morgan Stanley and Oppenheimer & Co. Inc., focusing on equity research and corporate banking. An MBA in Corporate Finance from NYU Stern School of Business complements a Bachelor of Commerce degree from McMaster University.